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OBJECTIVE — Exenatide improves postprandial glycemic excursions in type 2 diabetes.
Exenatide could beneﬁt type 1 diabetes as well. We aimed to determine an effective and safe
glucose-lowering adjuvant exenatide dose in adolescents with type 1 diabetes.
RESEARCH DESIGN AND METHODS — Eight subjects completed a three-part dou-
ble-blinded randomized controlled study of premeal exenatide. Two doses of exenatide (1.25
and 2.5 g) were compared with insulin monotherapy. Prandial insulin dose was reduced by
20%. Gastric emptying and hormones were analyzed for 300 min postmeal.
RESULTS — Treatment with both doses of exenatide versus insulin monotherapy signiﬁ-
cantly reduced glucose excursions over 300 min (P  0.0001). Exenatide administration failed
to suppress glucagon but delayed gastric emptying (P  0.004).
CONCLUSIONS — Adjunctive exenatide therapy reduces postprandial hyperglycemia in ado-
lescentswithtype1diabetes.Thisreductioninglucoseexcursionoccursdespitereductionininsulin
dose. We suggest that exenatide has therapeutic potential as adjunctive therapy in type 1 diabetes.
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I
ntensive insulin therapy delays/
preventscomplicationsassociatedwith
type 1 diabetes (1,2). However, insulin
monotherapy fails to achieve normogly-
cemia (3). Postprandial hyperglycemia
and hypoglycemia (4,5) continue to cre-
ate impediments to management. Even
the closed-loop system fails to normalize
postprandial hyperglycemia (6). Addi-
tional therapies to insulin are needed to
achieve optimal glycemic control.
Glucagon-like peptide (GLP)-1 is an
incretin secreted in response to nutrient
ingestion (7). Physiological GLP-1 en-
hances insulin secretion, delays gastric
emptying, and suppresses glucagon. But
because of its short half-life (8), it is un-
suitable for clinical application.
Exenatideisalong-actingGLP-1recep-
tor agonist and acts similarly to native
GLP-1(9).Exenatideiseffectiveindecreas-
ing postprandial hyperglycemia in type 2
diabetes (10). However, there are few stud-
ies using exenatide in type 1 diabetes and
none in adolescents. The objective of our
study was to examine the effect of adjuvant
premealexenatideandinsulinonpostpran-
dial glucose in type 1 diabetes and establish
an effective and safe glucose-lowering dose.
RESEARCH DESIGN AND
METHODS— Study was performed
with Baylor College of Medicine Institu-
tional Review Board approval, and in-
formedconsentwasobtainedinaccordance
with federal/institutional guidelines.
Subjects with type 1 diabetes using
multipledailyinjectionsorinsulinpump,
aged 13–22 years, with diabetes for 1
year, BMI 90th percentile for age, he-
moglobin12g/dl,andhemoglobinA1C
8.5% were recruited. One subject had
treated hypothyroidism with no other
chronic conditions. Subjects were not on
any concomitant medications, which af-
fected blood glucose concentrations.
Pregnant/lactating females were ex-
cluded. Two subjects failed screening.
One subject had hypoglycemia needing
rescue glucose boluses with insulin alone
and did not participate in further studies.
Eight subjects completed the three-
part study. Followed by a baseline study
withinsulinalone,subjectswererandom-
ized to two different doses of exenatide
(1.25and2.5g),administeredinadou-
ble-blinded randomized controlled man-
ner. Studies were at least 3 weeks apart.
All subjects had type 1 diabetes (antibody
positive),withminimalornoendogenous
C-peptide response to meals. (A pilot
study done previously suggested that
higher doses [7–10 g] of exenatide used
in normal BMI subjects with type 1 dia-
betes resulted in hypoglycemia, and
hencethelowereddoseswereexamined.)
Baseline
At 0800 h, the prebreakfast insulin bolus
wasadministeredbasedonpatient’susual
insulin-to-carbohydrate ratio. Postbolus,
subjects drank 12 ounces of a standard
liquid meal (Boost High Protein Drink,
360calories,50gcarbohydrates,and12g
fat), enriched with1go f[
13C]glucose
within 10 min. Breath samples for
13CO2
analysis were collected in duplicates at 17
time points until 1300 h. Usual insulin
basal rates or glargine were maintained
during study.
On the days subjects received the
study drug of 1.25 g( 0.02 g/kg) or
2.5 g( 0.04 g/kg) exenatide along
with insulin, the prandial insulin was re-
duced by 20%.
Measurements
Plasma glucose was measured using a
bedside YSI glucose analyzer (2300 Stat
Plus; Yellow Springs Instruments, Yellow
Springs,OH)throughoutthestudyatreg-
ularly timed intervals. Blood samples
werecollectedpre-andpostprandiallyfor
exenatide,insulin,C-peptide,GLP-1,and
glucagon. Blood was processed as previ-
ously described elsewhere (11).
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tem (Bayer, Elkhart, IN) was used for
measuring the percentage concentration
of hemoglobin A1C.
Hormonal analysis and
13CO2 was
measured as previously described else-
where (12).
Statistical analysis
Repeated-measures ANOVA models were
applied for each variable. If treatment ef-
fect was signiﬁcant, then pairwise com-
parisons in treatment means were made
among three groups with Tukey’s multi-
ple comparison procedure adjustment.
The analyses were performed using SAS
version 9.2.
Graphs were generated using Graph
PadPrismversion5(GraphPadSoftware,
SanDiego,CA).Areaunderthecurvewas
calculatedusingthetrapezoidalrule.Data
were considered signiﬁcant at P  0.05.
RESULTS— Subjects were 17  1
years (range 15.8–18), had diabetes for
5  3.3 years, weighed 67  8.7 kg, had
aBMIof23.82.1kg/m
2,hadanA1Cof
7.4  0.7%, and had a total daily insulin
dose of 0.9  0.2 units/kg/day.
Postprandial hyperglycemia was re-
duced with 1.25 and 2.5 g adjunctive ex-
enatide versus insulin monotherapy (P 
0.0001) (Fig. 1). Delta plasma glucose area
underthecurve(AUC0–120)wasreducedin
theearlypostprandialperiodinstudieswith
1.25 g (49  156 mmol/l per min) (P 
0.008) and 2.5 g (44  281 mmol/l per
min) exenatide versus insulin alone (379
259 mmol/l per min) (P  0.007).
Figure1—Glucose(A),breathanalysis(B),glucagon(C),GLP-1(D),C-peptide(E),andinsulin(F)concentrationswithinsulinmonotherapy(●),
1.25 g(  ) and 2.5 g of exenatide (▫) after a mixed meal.
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13CO2 in breath was signiﬁcantly delayed
with 1.25 g exenatide versus insulin
alone (P  0.004) and 2.5 g exenatide
when compared with insulin mono-
therapy (P  0.0001).
Glucagon and C-peptide concentra-
tions were not statistically different be-
tween studies using exenatide versus
insulin alone (P  0.1 and P  0.06, re-
spectively). GLP-1 was lower with 2.5 g
exenatide compared with insulin (P 
0.0001) but not with 1.25 g exenatide
(P  0.2).
Insulin levels were lower between ex-
enatide groups versus insulin alone (P 
0.0001), as expected with a 20% reduc-
tion in insulin.
Adverse events
One subject had nausea with both ex-
enatide doses and received ondansetron,
and another had nausea with the 2.5-g
dose; none had emesis. One subject who
was hypoglycemic at the outset of the
study (3.3 mmol/l) had further hypogly-
cemiaafterinjectionof1.25gexenatide,
reaching a nadir of 3.1 mmol/l, and re-
ceived one intravenous bolus of glucose.
CONCLUSIONS — Our study dem-
onstrates reduction in postprandial glu-
cose after exenatide injection in
adolescents with type 1 diabetes. These
effects were associated with delayed gas-
tric emptying, and the results are consis-
tent with published studies in adults
(13,14).However,asopposedtoprevious
reports, glucagon suppression was not
noted with exenatide, which could be be-
cause of the small sample size of our
study.
Both exenatide doses were compara-
ble in reducing postprandial glucose ex-
cursions, and hence the lower dose could
be tested as an initial dose and titrated to
response and tolerability in a larger co-
hortofsubjects.Pharmacokineticdataare
included in the online appendix (avail-
able at http://care.diabetesjournals.org/
cgi/content/full/dc09-1959/DC1), and
data are comparable to adults. Caution
must be exercised if blood glucose is low
to omit exenatide or use lowered insulin
and/or exenatide dose.
In conclusion, adjunctive exenatide
therapy has therapeutic potential in ado-
lescents with type 1 diabetes. Further
studies are ongoing using exenatide for a
4-month period.
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